Inventor · disambiguated record
Naomi Barak
Also filed as: BARAK NAOMI
5 granted patents·7 pending applications·0 citations·filing 2012–2021
57Inventor score
Top patents by PatentIndex Score
12 records- 0160US2024287048A1Substituted acyl sulfonamides for treating cancerBROAD INST INC·Filed 2021·Application pending·0 cites
- 0254US2023192700A1Pyrazolopyrazines acting on cancers via inhibition of cdk12BAYER AG·Filed 2021·Application pending·0 cites
- 0353US2023106032A1Imidazotriazines acting on cancer via inhibition of cdk12BAYER AG·Filed 2021·Application pending·0 cites
- 0451US2024279207A1Substituted acyl sulfonamides for treating cancerBROAD INST INC·Filed 2021·Application pending·0 cites
- 0551US2023117034A1PyrazolotriazinesBAYER AG·Filed 2020·Application pending·0 cites
- 0643US12357603B2Acyl sulfonamides for treating cancerBAYER AG·Filed 2020·Granted Jul 15, 2025·0 cites·17 claims
- 0740US9714266B2Estra-1,3,5(10),16-tetraene-3-carboxamides for inhibition of 17.beta.-hydroxysteroid dehydrogenase (AKR1C3)Bayer Pharma AG·Filed 2014·Granted Jul 25, 2017·0 cites·10 claims
- 0839US9512169B23-substituted estra-1,3,5(10),16-tetraene derivatives, methods for the production thereof, pharmaceutical preparations containing same, and use thereof for the production of medicamentsBayer Pharma AG·Filed 2013·Granted Dec 6, 2016·0 cites·10 claims
- 0936US9487554B2Estra-1,3,5(10),16-tetraene-3-carboxamide derivatives, processes for their preparation, pharmaceutical preparations comprising them and their use for preparing medicamentsBAYER IP GMBH·Filed 2012·Granted Nov 8, 2016·0 cites·8 claims
- 1028US10023539B2Aryl-cyanoguanidine compoundsBayer Pharma AG·Filed 2015·Granted Jul 17, 2018·0 cites·14 claims
- 1128US2018118722A1Novel aryl-cyanoguanidine compoundsBayer Pharma AG·Filed 2016·Application pending·0 cites
- 1226US2018099937A1Novel aryl-cyanoguanidine compoundsBayer Pharma AG·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Naomi Barak files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →